Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barzolvolimab in prurigo nodularis
2023-510279-80-00Phase 2Authorised
- Sponsor
- Celldex Therapeutics
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of barzolvolimab in prurigo nodularis (PN) (3 arms), sponsored by Celldex Therapeutics. Planned start Aug 2024; status: authorised.
02
Drugs
barzolvolimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2023-510279-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510279-80-00.